

STAMPEDE Abiraterone Latitude Criteria (All M1 patients)		ADT Alone	ADT + AAP			
		No. of events/ No. of patients		Adjusted HR (95% CI)		Interaction between metastatic subgroups p-value
Overall Survival						
	Overall	195/452	135/449		0.61 (0.49-0.79)	
	Low	53/220	41/208		0.66 (0.44-0.98)	
	High	142/232	94/241		0.54 (0.41-0.70)	0.39
Failure Free Survival						
	Overall	345/452	191/449		0.32 (0.26-0.37)	
	Low	152/220	56/208		0.24 (0.17-0.33)	
	High	202/232	135/241		0.31 (0.25-0.39)	0.29
Skeletal Related Events						
	Overall	164/452	93/449		0.47 (0.36-0.60)	
	Low	49/220	17/208		0.31 (0.18-0.54)	
	High	115/232	76/241		0.48 (0.36-0.64)	0.21
Progression Free Survival						
	Overall	267/452	158/449		0.45 (0.37-0.54)	
	Low	101/220	41/208		0.33 (0.23-0.48)	
	High	166/232	117/241		0.46 (0.36-0.59)	0.16
Prostate Cancer Specific Death						
	Overall	172/452	114/449		0.59 (0.46-0.75)	
	Low	49/220	27/208		0.51 (0.31-0.84)	
	High	123/232	87/241		0.57 (0.43-0.75)	0.73

0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2

Favours ADT + AAP

← Favours ADT →